Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) — Stella
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(8 sites)
Australia
Chris O'Brien Lifehouse, Camperdown, New South Wales
Monash Medical Centre, Clayton, New South Wales
Royal North Shore Hospital, St Leonards, New South Wales
Westmead Hospital, Westmead, New South Wales
Wollongong Hospital, Wollongong, New South Wales
Princess Alexandra Hospital, Woolloongabba, Queensland
Flinders Medical Centre, Bedford Park, South Australia